Details of the Drug Reposition

General Information of This Drug (ID: DM8HLO5)

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

3 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Autosomal dominant familial periodic fever	DISCRNV1	N.A.	Approved	[1]
Cryopyrin-associated periodic syndromes	DISZE4FB	4A60.1	Approved	[2]
Rheumatoid arthritis	DISTSB4J	FA20	Approved	[2]
------------------------------------------------------------------------------------

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Vasculitis	DISQRKDX	4A44	Phase 2	[2]
Urticaria	DIS9WQAI	EB00-EB05	Phase 2	[2]
------------------------------------------------------------------------------------

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Mevalonate kinase deficiency	DISSTRVK	N.A.	Discontinued in Phase 2	[3]
------------------------------------------------------------------------------------

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Familial Mediterranean fever	DISVP5WP	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

References

1	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018 May 17;378(20):1908-1919.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6773).
3	Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
4	Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci. 2020 Nov 3;50(SI-2):1591-1610.